ZURICH, Jan 21 (Reuters) - U.S. regulators have approved Novartis AG's (NOVN.VX: Quote, Profile, Research) Tekturna blood-pressure pill in combination with the diuretic hydrochlorothiazide (HCT), the Swiss drugmaker said on Monday. The Food and Drug Administration approved a combination of Tekturna, co-developed by Swiss biotech company Speedel (SPPN.S: Quote, Profile, Research), with HCT in a single tablet.
